Merck reports HCV triple combo data

Merck & Co. Inc. (NYSE:MRK) announced results from three Phase II trials evaluating its triple combination therapy MK-3682B to treat chronic HCV infection.

Pooled results from the part B portion of the C-CREST-1 and 2 studies showed MK-3682B led to an SVR12 after eight weeks of treatment in 95%, 86% and 95% of patients with HCV genotype 1, 2 and 3 infection, respectively, with or without cirrhosis. ...